Compounds > 4,4',6-trimethylangelicin
Page last updated: 2024-12-07

4,4',6-trimethylangelicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4',6-trimethylangelicin: new monofunctional furocoumarin; potential agent for photochemotherapy of psoriasis; capable of photoreacting with DNA to a large extent forming only monoadducts; produces singlet oxygen to an insignificant extent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107731
CHEMBL ID173365
CHEBI ID82543
SCHEMBL ID17174622
MeSH IDM0123355

Synonyms (24)

Synonym
4,6,9-trimethyl-2h-furo[2,3-h]chromen-2-one
4,6,4'-trimethylangelicin
4,6,9-trimethyl-2h-furo(2,3-h)-1-benzopyran-2-one
4-hydroxy-beta,3,7-trimethyl-5-benzofuranacrylic acid delta-lactone
4,4',6-trimethylangelicin
4,6,9-trimethyl-2h-furo(2,3-h)(1)benzopyran-2-one plus ultraviolet a radiation
4,4',6-trimethylangelicin plus ultraviolet a radiation
brn 4467945
ccris 4277
4,4,6-trimethylangelicin
2h-furo(2,3-h)-1-benzopyran-2-one, 4,6,9-trimethyl-
2h-furo(2,3-h)(1)benzopyran-2-one, 4,6,9-trimethyl, plus ultraviolet a radiation
90370-29-9
CHEMBL173365
chebi:82543 ,
4,6,9-trimethylfuro[2,3-h]chromen-2-one
C19538
unii-t2myr3390l
t2myr3390l ,
AKOS025119188
SCHEMBL17174622
DTXSID20238106
Q27156054
BB 0266510

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In contrast with in vitro experiments, photobinding of CPZ to epidermal DNA/RNA was not found in vivo; apparently the bioavailability in the nucleus is very low."( Photobinding of 8-methoxypsoralen, 4,6,4'-trimethylangelicin and chlorpromazine to Wistar rat epidermal biomacromolecules in vivo.
Beijersbergen van Henegouwen, GM; Caffieri, S; Dall'Acqua, F; Persons, CC; Schoonderwoerd, SA, 1991)		0.28
" In this current study, cellular bioavailability of 8-MOP, TMA and CPZ was investigated in vitro, using low doses of UVA relevant for the clinical setting of ECP."( Phototoxicity, distribution and kinetics of association of UVA-activated chlorpromazine, 8-methoxypsoralen, and 4,6,4'-trimethylangelicin in Jurkat cells.
Dobrucki, J; Rajwa, B; Sarna, T; Skrzeczyńska-Moncznik, J; van Henegouwen, GB; Wolnicka-Głubisz, A, 2005)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
furanocoumarinAny furochromene that consists of a furan ring fused with a coumarin. The fusion may occur in different ways in give several isomers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID54115Compound was evaluated for the binding parameter by determining the number of nucleotides occluded by a bound angelicin (n)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357671Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 1 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357658Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 10 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID16264Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89071Erythema induction by 8-methoxypsoralen (8-MOP) for comparison at dose of 4 J/cm e2 ultraviolet-A radiation in female patient; +++=very strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID619965Inhibition of NF-KB p50 subunit/DNA interaction after 20 mins by EMSA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: design, synthesis and biological effects.
AID88890Number of treatments at dose of 10 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID88892Number of treatments at dose of 6 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89080Erythema induction by the compound at dose of 8 J/cm e2 ultraviolet-A radiation in female patient; - = absent1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357654Induction of damage in salmon testes DNA at 100 uM in presence of 2.5 to 7.5 J/cm2 UVA irradiation by ethidium bromide dye-based agarose gel electrophoresis analysis2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID90073Pigmentation capacity of 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; + = moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90078Pigmentation capacity at dose of 10 J/cm e2 ultraviolet-A radiation in female patient; ++=strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID88893Number of treatments at dose of 8 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID16271Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357674Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 50 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID89078Erythema induction by the compound at dose of 4 J/cm e2 ultraviolet-A radiation in female patient; - = absent1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90079Pigmentation capacity at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; + = moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89070Erythema induction by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation in female patient; +++=very strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89073Erythema induction by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; +++ = very strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357668Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 10 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID16270Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357669Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 50 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357665Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 100 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357667Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 5 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID90083Pigmentation capacity at dose of 9 J/cm e2 ultraviolet-A radiation in female patient; +=moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89072Erythema induction by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; ++ = strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID16268Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID91202Number of treatments at dose of 6 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357663Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 10 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID16265Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID16266Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90071Pigmentation capacity of 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation in female patient; +=moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357660Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 100 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID89074Erythema induction by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation in female patient, +=moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID89077Erythema induction by the compound at dose of 10 J/cm e2 ultraviolet-A radiation in female patient; - = absent1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90074Pigmentation capacity of 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; ++ = strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID54807Compound was evaluated for the binding parameter by determining rate constant1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID54116Compound was evaluated for the frequency of the binding site that is the number of molecules bound to every nucleotide (1/n)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357656Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 5 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID16269Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357662Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 5 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357670Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 100 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357659Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 50 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID88891Number of treatments at dose of 4 J/cm e2 ultraviolet-A radiation (female patient)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID130473Compound was evaluated for 50% inhibition of DNA synthesis in Ehrlich ascites tumor cells by irradiation (365 nM) at 1.9 x 10e -5M incubated with [3H]thymidine at 37 degree C (p 0.05)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90072Pigmentation capacity of 8-methoxypsoralen (8-MOP) for comparison at dose of 4 J/cm e2 ultraviolet-A radiation in female patient; - = absent1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357701Inhibition of NF-kappaB (unknown origin) assessed as decrease in NF-kappaB/DNA interaction at 12.5 to 100 uM using 32P-labeled target NF-kappaB double-stranded oligonucleotide after 30 mins by EMSA2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357666Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 1 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357657Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 1 uL/plate in absence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357672Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 5 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357675Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 100 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID89079Erythema induction by the compound at dose of 6 J/cm e2 ultraviolet-A radiation in female patient; - = absent1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357673Genotoxicity in Salmonella typhimurium TA100 assessed as revertant colonies at 10 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID54459Compound was evaluated for the association constant to an isolated site of DNA1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357661Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 1 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID90080Pigmentation capacity at dose of 8 J/cm e2 ultraviolet-A radiation in female patient; +++=very strong1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID90075Pigmentation capacity of 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation in female patient; +=moderate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID1357664Genotoxicity in Salmonella typhimurium TA98 assessed as revertant colonies at 50 uL/plate in presence of Sprague-Dawley rat S9 metabolic activation after 72 hrs by Ames test (Rvb = 1 No_unit)2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
AID1357702Induction of damage in salmon testes DNA at 100 uM in absence of 2.5 to 7.5 J/cm2 UVA irradiation by ethidium bromide dye-based agarose gel electrophoresis analysis2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (18.18)18.7374
1990's21 (47.73)18.2507
2000's5 (11.36)29.6817
2010's9 (20.45)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.95 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.27%)6.00%
Case Studies2 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other41 (93.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.7830halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		3.1150organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		4.18170aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
trioxsalen
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.. lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.. antipsoriatic : A drug used to treat psoriasis.. trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.		2.9240psoralensdermatologic drug;
photosensitizing agent
ficusin
Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.		2.0610psoralensplant metabolite
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		2.5320
angelicin
angelicin: used as tranquillizer; sedative; or anticonvulsant; structure		3.0950furanocoumarin
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		2.0110acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
pyrido(3,4-c)-7-methylpsoralen
pyrido(3,4-c)-7-methylpsoralen: structure given in first source		1.9710furanocoumarin
4,5'-dimethylangelicin
[no description available]		2.420furanocoumarin
5-methylangelicin
[no description available]		1.9610furanocoumarin
3-carbethoxypsoralen
[no description available]		7.3820ethyl ester;
psoralens
4,4'-dimethylangelicin
4,4'-dimethylangelicin: structure given in first source		1.9610furanocoumarin
lumacaftor
lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source. lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis.		2.5320aromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines		CFTR potentiator;
orphan drug
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0610
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.3920benzenes;
hydroxycoumarin;
methyl ketone
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		02.6630
Palmoplantaris Pustulosis
[description not available]		02.8840
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		02.8840
Cystic Fibrosis of Pancreas
[description not available]		04.1150
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		04.1150
Disease Exacerbation
[description not available]		02.3110
Bladder Cancer
[description not available]		02.3110
Carcinoma, Anaplastic
[description not available]		02.3110
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.3110
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.3110
Cancer of Prostate
[description not available]		02.1710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1710
Electron Transport Chain Deficiencies, Mitochondrial
[description not available]		02.1310
Mitochondrial Diseases
Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.		02.1310
HbS Disease
[description not available]		02.0510
Anemia, Cooley's
[description not available]		02.0510
Anemia, Sickle Cell
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.		02.0510
beta-Thalassemia
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.		02.0510
Cancer, Radiation-Induced
[description not available]		02.6830
Cancer of Skin
[description not available]		02.940
Cocarcinogenesis
The combination of two or more different factors in the production of cancer.		02.3820
Skin Neoplasms
Tumors or cancer of the SKIN.		02.940
Dermatoses
[description not available]		01.9910
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		01.9910
Anemia, Fanconi
[description not available]		01.9910
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		01.9910
B16 Melanoma
[description not available]		01.9710
Contact Dermatitis
[description not available]		01.9710
Actinic Reticuloid Syndrome
[description not available]		01.9710
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		01.9710
Digitate Dermatosis
[description not available]		01.9710
Mycosis Fungoides
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.		01.9710
Parapsoriasis
The term applied to a group of relatively uncommon inflammatory, maculopapular, scaly eruptions of unknown etiology and resistant to conventional treatment. Eruptions are both psoriatic and lichenoid in appearance, but the diseases are distinct from psoriasis, lichen planus, or other recognized dermatoses. Proposed nomenclature divides parapsoriasis into two distinct subgroups, PITYRIASIS LICHENOIDES and parapsoriasis en plaques (small- and large-plaque parapsoriasis).		01.9710